Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 5mg - rosuvastatin (rosuvastatin calcium) 5mg

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 10mg - rosuvastatin (rosuvastatin calcium) 10mg

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 20mg - rosuvastatin (rosuvastatin calcium) 20mg

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 40mg - rosuvastatin (rosuvastatin calcium) 40mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

United States - English - NLM (National Library of Medicine)

h. j. harkins company inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.3 hypertriglyceridemia rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.4 primary dysbetalipoproteinemia (type iii hyperlipoproteinemia) rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). 1.5 adult patients with homozygous familial hypercholesterolemia rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. 1.8 limitations of use rosuvastatin cal

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - rosuvastatin (as calcium salt) 20 mg - (as calcium salt) 20 mg